FogPharma and ARTBIO Announce Collaboration to Co-Develop Multiple Helicon™-Enabled Alpha-Particle Radioligand Therapies for the Treatment of Cancer
CAMBRIDGE, Mass.--(BUSINESS WIRE)--FogPharma®, a clinical-stage biopharmaceutical company dedicated to delivering a new class of therapies that go beyond the limits of currently available medicines using its Helicon™ peptide platform, and ARTBIO, Inc. (“ARTBIO”), a clinical-stage radiopharmaceutical company developing a new class of 212Pb alpha radioligand therapies (ARTs), announced a collaboration to co-develop Helicon-enabled ARTs (HEARTs) to transform outcomes for patients with multiple types of cancer.
FogPharma Announces $145 Million Financing
We all aspire to have a boss who will just give you money for your next endeavor. Mathai Mammen, M.D., Ph.D., happens to have just that.
FogPharma to Present at the 42nd Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--FogPharma®, a biopharmaceutical company committed to transforming the lives of patients through a new precision medicine approach widely applicable to important and challenging intracellular targets, today announced the first patient has been dosed in a first-in-human Phase 1/2 clinical trial of, FOG-001, the company’s first-in-class TCF-blocking ?-catenin inhibitor. FOG-001 represents the first development candidate arising from FogPharma’s pioneering Helicon™ therapeutics, a new class of drugs capable of modulating protein-protein interactions that may otherwise be challenging to drug.
Mathai Mammen, M.D., Ph.D., to Join FogPharma as Chairman, President and Chief Executive Officer
Coming off a $107 million series C round in March 2021, FogPharma spirits were high and aspirations for its “universal druggability” platform were through the roof. Now, the company has even more reason to be confident, closing a new gargantuan funding round.
FogPharma Announces $178 Million Series D Financing to Advance Pipeline of First-in-Class Helicon Polypeptide Therapeutics Targeting Major Cancer Drivers
CAMBRIDGE, Mass.--(BUSINESS WIRE)--FogPharma, a biopharmaceutical company pioneering a new class of precision medicines that could ultimately prove applicable to all therapeutic targets, including those previously considered “undruggable,” today announced the selection of its lead product development candidate, FOG-001, a first-and-only-in-class direct ?-catenin inhibitor. FOG-001 represents the first of FogPharma’s proprietary, conformationally hyperstabilized ?-helical polypeptides (Helicon polypeptides), a new class of therapeutics designed to combine the targeting strength and specificity of antibodies with the broad tissue distribution, intracellular target engagement and oral dosing optionality of small molecules.